Translational Research Collaborations Unit (TRCU)
Group Leader:
Dr Valeria Pavet
Accelerating Cancer Research Into Clinical Impact
The Translational Research Collaborations Unit (TRCU) bridges the gap between scientific discovery and clinical application by developing preclinical translational research programmes in partnership with biotechnology and pharmaceutical companies. Our mission is to accelerate the development of innovative cancer therapies through robust preclinical evaluation, advanced disease models, and strategic industry collaborations.
Working at the interface of academia, industry, and clinical research, we generate the evidence needed to advance promising therapeutic strategies toward clinical trials and ultimately improve outcomes for cancer patients.
Our Impact
- Collaborations with more than 30 industry partners worldwide.
- Partnerships spanning over 40 academic institutions.
- Focused expertise in translational oncology and preclinical drug development.
- Advanced in vitro and in vivo cancer modelling platforms.
- Support for academic and commercial therapeutic innovation.
About Us
Who We Are
The TRCU is dedicated to translating innovative cancer research into clinically actionable opportunities. We combine biological insight, translational expertise, and industry engagement to evaluate emerging therapeutic approaches and support their progression toward patient benefit.
Our team works closely with researchers across the CRUK Scotland Institute, the CRUK Scotland Centre, technology platforms, clinician-scientists, and industrial partners to create impactful translational programmes.
Research & Services
Preclinical Translational Research
We deliver comprehensive translational programmes designed to generate efficacy, mechanism-of-action, biomarker, and target-engagement data that inform therapeutic decision-making and clinical development.
Key Capabilities
Drug Discovery and Development Support
- Evaluation of novel therapeutics and drug combinations
- Mechanistic studies and resistance investigations
- Biomarker discovery and validation
- Translational strategy development
- Generation of preclinical data packages for investors and partners
Advanced Cancer Models
The TRCU has access to a comprehensive portfolio of cancer models including colorectal cancer, liver cancer, pancreatic cancer, ovarian cancer and melanoma, amongst others.
In Vitro Platforms
We utilise advanced two-dimensional and three-dimensional culture systems derived from human and mouse tissues to explore tumour biology, therapeutic responses, and treatment resistance in biologically relevant systems.
In Vivo Platforms
Our in vivo capabilities include:
- Orthotopic allograft models
- Genetically Engineered Mouse Models (GEMMs)
- Patient-Derived Xenograft (PDX) models
These platforms provide robust systems for evaluating candidate therapeutics and identifying clinically relevant biomarkers.
Current Research Focus Areas
Targeting Key Cancer Pathways
Our programmes investigate therapeutic opportunities across multiple cancer-driving pathways for thedevelopment and evaluation of targeted inhibitors and combination approaches designed to overcome therapeutic resistance. Our research programmes are currently focused on studying the impact of therapies in tumour progression, stromal interactions, epithelial-to-mesenchymal transition and modification of the immune landscape.
Industry Partnerships
Partnering for Translational Success
The TRCU works with leading biotechnology and pharmaceutical organisations to validate emerging therapeutic concepts and accelerate their path toward clinical development. Through these collaborations, we generate preclinical evidence that supports investment decisions, commercialisation strategies, and progression into clinical evaluation.
Building Strategic Collaborations
The TRCU acts as a hub for translational research collaboration across the Institute and wider cancer research community and has supported the establishment of collaborations between the CRUK Scotland Institute Teams with more than 30 industry partners and over 40 academic institutions worldwide.
The unit also works closely with clinician-scientists, Institute technology platforms, and investigators across the CRUK Scotland Institute and CRUK Scotland Centre, ensuring translational programmes remain aligned with clinical need and emerging opportunities.
Technology Platforms
Enabling Research Excellence
Our programmes are supported by close collaboration with:
- Biological Research Unit
- Histology Platform
- Advanced Imaging Centre
- Molecular Biology Services
These specialist platforms provide the infrastructure, technologies, and expertise necessary to deliver high-quality translational research and preclinical drug development programmes.
Collaborate With Us
Whether you are a biotechnology company, pharmaceutical organisation, academic investigator, or clinical researcher, the TRCU offers expertise and preclinical platforms to accelerate translational oncology programmes.
Areas of Collaboration
- Preclinical therapeutic evaluation
- Biomarker development
- Translational strategy
- Drug combination studies
- Cancer model development
- Academic-industry partnerships
Let’s work together to transform scientific discoveries into new cancer therapies.
Contact Us
For discussing collaborations, please contact Valeria Pavet at: v.pavet@crukscotlandinstitute.ac.uk
For contracts and agreements, please contact contracts@crukscotlansinstitute.ac.uk

Lab Members

Recent Publications
Recent Publications
2026
Pardo, L., Moore, M., Deshmukh, R., Powley, I., Waldron, J.A., Kruspig, B., McGarry, L., Dolma, L., Campos, A.V., Wood, C., Leslie, H., Hughes, M., Jeldes, E., Munro, J., Mitchell, L., Officer-Jones, L., Baird, R., Coquelet, H., Jamieson, N.B., Sumpton, D., Strathdee, D., le Quesne, J., Bushell, M., Murphy, D.J., Norman, J.C., 2026. Increased mRNA translation delays tumour initiation and exposes a therapeutic vulnerability in lung cancer. Mol Cancer.
Williams, H.L., Poulain, N., Powley, I., Martinelli, S., Bielik, R., Leslie, H., Nixon, C., Wilson, C.R., Sereno, M., He, Z., Officer-Jones, L., Ballantyne, F., Pennie, R., Wood, C.S., Lewis, D.Y., Jamieson, N.B., Le Quesne, J., 2026. Spatial Molecular Plasticity Underpins Lethal Morphologies in Lung Adenocarcinoma. Mod Pathol 100960.
2025
Baird, R.L., Mason, D., Rakovic, K., Ballantyne, F., Powley, I.R., Georgakopoulou, A., Hillary, L., Bird, T.G., Officer-Jones, L., Le Quesne, J., 2025. PixlMap: A generalisable pixel classifier for cellular phenotyping in multiplex immunofluorescence images. PLoS One 20(12), e0317865.
Kanellos, G., Giacomelli, C., Raven, A., Vlahov, N., Jin, H., Herviou, P., Malla, S.B., Nasreddin, N., Centeno, P.P., Alexandrou, C., Gilroy, K., Baird, R.L., Pennel, K., Munro, J., Waldron, J.A., Hall, H., Officer-Jones, L., Bryson, S., Strathdee, D., Lilla, S., Zanivan, S., Morrison, V., Nixon, C., Ridgway, R.A., Miller, C., Knight, J.R.P., Campbell, A.D., Dunne, P.D., Le Quesne, J., Edwards, J., Park, P.J., Bushell, M., Sansom, O.J., 2025. Nucleophosmin supports WNT-driven hyperproliferation and tumor initiation. Nat Genet 58, 100–115.
Müller, M., May, S., Hall, H., Kendall, T.J., McGarry, L., Blukacz, L., Nuciforo, S., Georgakopoulou, A., Jamieson, T., Phinichkusolchit, N., Dhayade, S., Suzuki, T., Huguet-Pradell, J., Powley, I.R., Officer-Jones, L., Pennie, R.L., Esteban-Fabró, R., Gris-Oliver, A., Pinyol, R., Skalka, G.L., Leslie, J., Hoare, M., Sprangers, J., Malviya, G., Mackintosh, A., Johnson, E., McCain, M., Halpin, J., Kiourtis, C., Nixon, C., Clark, G., Clark, W., Shaw, R., Hedley, A., Drake, T.M., Tan, E.H., Neilson, M., Murphy, D.J., Lewis, D.Y., Reeves, H.L., Le Quesne, J., Mann, D.A., Carlin, L.M., Blyth, K., Llovet, J.M., Heim, M.H., Sansom, O.J., Miller, C.J., Bird, T.G., 2025. Human-correlated genetic models identify precision therapy for liver cancer. Nature.
Seyedshahi, F., Rakovic, K., Poulain, N., Claudio Quiros, A., Powley, I.R., Richards, C., Uraiby, H., Klebe, S., Moore, D.A., Nakas, A., Wilson, C.R., Sereno, M., Officer-Jones, L., Ficken, C., Teodosio, A., Ballantyne, F., Murphy, D., Yuan, K., Le Quesne, J., 2025. A histomorphological atlas of resected mesothelioma discovered by self-supervised learning from 3446 whole-slide images. Nat Commun 16(1), 8891.
White, M., Mills, M.L., Millett, L.M., Gilroy, K., Hong, Y., Zeiger, L.B., Simpson, R.J., Corry, S.M., Ligeza, A., Lannagan, T.R.M., Susanti, S., Ridgway, R.A., Yazgili, A.S., Grzesiak, L., Amirkhah, R., Ford, C.A., Vlahov, N., Tovell, H., Officer-Jones, L., Ficken, C., Pennie, R., Najumudeen, A.K., Raven, A., Nasreddin, N., Chauhan, E., Papanastasiou, A.S., Nixon, C., Morrison, V., Jackstadt, R., Graham, J.S., Miller, C.J., Ross, S.J., Barry, S.T., Pavet, V., Wilson, R.H., Le Quesne, J., Dunne, P.D., Tejpar, S., Leedham, S., Campbell, A.D., Sansom, O.J., 2025. MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance. Nature.
2024
Williams, H.L., Poulain, N., Powley, I., Martinelli, S., Bielik, R., Leslie, H., Nixon, C., Wilson, C.R., Sereno, M., He, Z., Officer-Jones, L., Ballantyne, F., Pennie, R., Wood, C.S., Lewis, D.Y., Jamieson, N.B., Le Quesne, J., 2024. Spatial resolution of transcriptomic plasticity states underpinning lethal morphologies in lung adenocarcinoma. bioRxiv.
Xavier, V., Martinelli, S., Corbyn, R., Pennie, R., Rakovic, K., Powley, I.R., Officer-Jones, L., Ruscica, V., Galloway, A., Carlin, L.M., Cowling, V.H., Le Quesne, J., Martinou, J.C., MacVicar, T., 2024. Mitochondrial double-stranded RNA homeostasis depends on cell-cycle progression. Life Sci Alliance 7.
Group Leader
Valeria Pavet*
Information about this team member’s research interests, experience, and background will be added soon. Please check back for updates.
Lab Members
Translational Scientist
Nikola Vlahov*
Translational Officer
Xue Hui Tan*
Scientific Officer
Rohan Dravid*
Contracts Manager

